ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years
Liu Yang
Matched on ORCID iD 0000-0001-7587-312X; OpenAlex author ID A5100619825. Sources: OpenAlex.
Their work
- Papers
- 16 (first author 1, last author 8)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 36
2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers
Papers 16
- A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment. Last author DOI 10.1016/j.canlet.2025.217934↗
- IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC. Co-author DOI 10.1016/j.celrep.2025.116476↗
- CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
- Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. Co-author DOI 10.1016/j.bbadis.2023.166852↗
- Evaluation of the Efficacy and Safety of Adjuvant Chemotherapy Regimens after Pancreatic Cancer Surgery: A Single-Center Real-World Study Last author DOI 10.21203/rs.3.rs-5316835/v1↗
- N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. Co-author DOI 10.1016/j.gendis.2022.02.014↗
- Third-line treatment options in metastatic pancreatic cancer patients: a real-world study. Last author DOI 10.3389/fonc.2023.1251258↗
- Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer? Last author DOI 10.1097/cad.0000000000001235↗
- Conversion Therapy of Unresectable Pancreatic Cancer: A Retrospective Study of the Real World Last author DOI 10.21203/rs.3.rs-674137/v1↗
- A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. Last author DOI 10.3389/fimmu.2021.691605↗
- Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2021.771247↗
- Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01220↗
- Immunotherapy in pancreatic cancer: New hope or mission impossible? Last author DOI 10.1016/j.canlet.2018.10.045↗
- LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription. Co-author DOI 10.1038/s41388-019-0918-z↗
- Establishment of pancreatic cancer stem cells by flow cytometry and their biological characteristics. Co-author PMID 26617845↗
- Bioinformatics method to predict two regulation mechanism: TF-miRNA-mRNA and lncRNA-miRNA-mRNA in pancreatic cancer. First author DOI 10.1007/s12013-014-0142-y↗
Closest collaborators
The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zheling Chen · 6 shared papers, 2021–2025 · strength 1.13
- Paper Third-line treatment options in metastatic pancreatic cancer patients: a real-world study. DOI 10.3389/fonc.2023.1251258↗
- Paper A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microen… DOI 10.1016/j.canlet.2025.217934↗
- Paper Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and … DOI 10.1097/cad.0000000000001235↗
- Jiahong Jiang · 5 shared papers, 2019–2023 · strength 0.66
- Paper N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. DOI 10.1016/j.gendis.2022.02.014↗
- Paper Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fonc.2021.771247↗
- Paper A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. DOI 10.3389/fimmu.2021.691605↗
- Peng-Fei Zhu · 2 shared papers, 2021–2023 · strength 0.43
- Qiaojun He · 2 shared papers, 2024–2025 · strength 0.42
- Paper Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. DOI 10.1016/j.bbadis.2023.166852↗
- Paper IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in P… DOI 10.1016/j.celrep.2025.116476↗
- Bo Yang · 2 shared papers, 2024–2025 · strength 0.42
- Paper Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. DOI 10.1016/j.bbadis.2023.166852↗
- Paper IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in P… DOI 10.1016/j.celrep.2025.116476↗
- Fujing Ge · 2 shared papers, 2024–2025 · strength 0.42
- Paper Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. DOI 10.1016/j.bbadis.2023.166852↗
- Paper IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in P… DOI 10.1016/j.celrep.2025.116476↗
- Mingxing Wang · 2 shared papers, 2021–2022 · strength 0.42
- Dongsheng Huang · 3 shared papers, 2019–2021 · strength 0.34
- Paper Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fonc.2021.771247↗
- Paper Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Can… DOI 10.3389/fonc.2020.01220↗
- Paper Immunotherapy in pancreatic cancer: New hope or mission impossible? DOI 10.1016/j.canlet.2018.10.045↗
- Wan‐Xin Peng · 2 shared papers, 2019–2023 · strength 0.33
- Yin‐Yuan Mo · 2 shared papers, 2019–2023 · strength 0.33
- Hongrui Lu · 1 shared paper, 2023 · strength 0.24
- Yunhua Liu · 1 shared paper, 2025 · strength 0.23
- Tao Song · 1 shared paper, 2024 · strength 0.23
- Xinyue Zhang · 1 shared paper, 2024 · strength 0.23
- Xiaoge Hu · 2 shared papers, 2019–2020 · strength 0.22
- Xin Dong · 1 shared paper, 2025 · strength 0.21
- Yulian Wu · 1 shared paper, 2025 · strength 0.21
- Jiewei Lin · 1 shared paper, 2025 · strength 0.18
- Jiayu Lin · 1 shared paper, 2025 · strength 0.18
- Yizhi Cao · 1 shared paper, 2025 · strength 0.18
- Shuyu Zhai · 1 shared paper, 2025 · strength 0.18
- Yihao Liu · 1 shared paper, 2025 · strength 0.18
- Jiancheng Wang · 1 shared paper, 2025 · strength 0.18
- Siyi Zou · 1 shared paper, 2025 · strength 0.18
- Chenlei Wen · 1 shared paper, 2025 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.